80 related articles for article (PubMed ID: 21856725)
21. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
[TBL] [Abstract][Full Text] [Related]
23. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
24. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
Gengenbacher M; Sebald HJ; Villiger PM; Hofstetter W; Seitz M
Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
[TBL] [Abstract][Full Text] [Related]
25. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
26. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
[TBL] [Abstract][Full Text] [Related]
28. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
Carmona L; Descalzo MA; Perez-Pampin E; Ruiz-Montesinos D; Erra A; Cobo T; Gómez-Reino JJ;
Ann Rheum Dis; 2007 Jul; 66(7):880-5. PubMed ID: 17324968
[TBL] [Abstract][Full Text] [Related]
29. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.
Cho SK; Sung YK; Kim D; Won S; Choi CB; Kim TH; Jun JB; Yoo DH; Bae SC
BMC Musculoskelet Disord; 2016 Aug; 17():333. PubMed ID: 27507033
[TBL] [Abstract][Full Text] [Related]
30. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
[TBL] [Abstract][Full Text] [Related]
31. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Agarwal SK; Glass RJ; Shadick NA; Coblyn JS; Anderson RJ; Maher NE; Weinblatt ME; Solomon DH
J Rheumatol; 2008 Sep; 35(9):1737-44. PubMed ID: 18634159
[TBL] [Abstract][Full Text] [Related]
32. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
Ciurea A; Exer P; Weber U; Tamborrini G; Steininger B; Kissling RO; Bernhard J; Scherer A;
Arthritis Res Ther; 2016 Mar; 18():71. PubMed ID: 27000865
[TBL] [Abstract][Full Text] [Related]
33. Early identification of golimumab-treated patients with higher likelihood of long-term retention.
García-Dorta A; González-Dávila E; Sánchez-Jareño M; Cea-Calvo L; Pombo-Suárez M; Sánchez-Alonso F; Castrejón I; Díaz-González F
Front Immunol; 2024; 15():1359571. PubMed ID: 38680482
[TBL] [Abstract][Full Text] [Related]
34. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Fernández-Espartero MC; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2011 Feb; 40(4):330-7. PubMed ID: 20864146
[TBL] [Abstract][Full Text] [Related]
35. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register.
Vela P; Sanchez-Piedra C; Perez-Garcia C; Castro-Villegas MC; Freire M; Mateo L; Díaz-Torné C; Bohorquez C; Blanco-Madrigal JM; Ros-Vilamajo I; Gómez S; Caño R; Sánchez-Alonso F; Díaz-González F; Gómez-Reino JJ
Arthritis Res Ther; 2020 Jun; 22(1):143. PubMed ID: 32539800
[TBL] [Abstract][Full Text] [Related]
36. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Cruz Fernández-Espartero M; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2011 Dec; 41(3):524-33. PubMed ID: 22152489
[TBL] [Abstract][Full Text] [Related]
37. Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry.
Pombo-Suárez M; Sanchez-Piedra C; Ruiz-Montesino D; Diaz-Torne C; Jovaní V; Cea-Calvo L; Castrejón I
Musculoskeletal Care; 2022 Jun; 20(2):403-407. PubMed ID: 34668303
[No Abstract] [Full Text] [Related]
38. Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results.
Titton DC; Silveira IG; Louzada-Junior P; Hayata AL; Carvalho HM; Ranza R; Rezende LS; Pinheiro GC; Santos JL; Miranda JR; Carvalho JF; Bertolo MB; Freire M; Scheinberg MA; Skare TL; Fernandes V; Bianchi W; Laurindo IM
Rev Bras Reumatol; 2011; 51(2):152-60. PubMed ID: 21584421
[TBL] [Abstract][Full Text] [Related]
39. [Biobadaser 2.0: analysis and trends in 2009].
Descalzo MÁ; Carmona L;
Reumatol Clin; 2010; 6(5):240-3. PubMed ID: 21794723
[TBL] [Abstract][Full Text] [Related]
40. Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.
Kubo S; Miyazaki Y; Todoroki Y; Nagayasu A; Kanda R; Aritomi T; Matsunaga S; Ueno M; Miyagawa I; Sonomoto K; Hanami K; Nakayamada S; Tanaka Y
Rheumatol Ther; 2023 Dec; 10(6):1705-1723. PubMed ID: 37856034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
